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Abstract
Activated lymphocytes release nano-sized vesicles (exosomes) containing microRNAs that can be monitored in the
bloodstream. We asked whether elicitation of immune responses is followed by release of lymphocyte-specific
microRNAs. We found that, upon activation in vitro, human and mouse lymphocytes down-modulate intracellular
miR-150 and accumulate it in exosomes. In vivo, miR-150 levels increased significantly in serum of humans
immunized with flu vaccines and in mice immunized with ovalbumin, and this increase correlated with elevation of
antibody titers. Immunization of immune-deficient mice, lacking MHCII, resulted neither in antibody production nor in
elevation of circulating miR-150. This study provides proof of concept that serum microRNAs can be detected, with
minimally invasive procedure, as biomarkers of vaccination and more in general of adaptive immune responses.
Furthermore, the prompt reduction of intracellular level of miR-150, a key regulator of mRNAs critical for lymphocyte
differentiation and functions, linked to its release in the external milieu suggests that the selective extracellular
disposal of microRNAs can be a rapid way to regulate gene expression during lymphocyte activation.
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Introduction
microRNAs (miRNAs) are RNA molecules of 18-25
nucleotides, that regulate gene expression post-
transcriptionally via direct interaction with specific sequences
present on target mRNAs [1]. miRNAs are present across most
species and are highly conserved. More than 2000 miRNAs
have been described in the human transcriptome (as for
miRBase, Release 19 http://microrna.sanger.ac.uk/) and their
control on gene targets has emerged as a critical regulatory
principle in mammals, including the immune system [2,3]. It has
been demonstrated that miRNAs are present in the
extracellular space associated with exosomes [4], which are
20- to 100-nm vesicles (or nanovesicles), formed through the
intracellular membrane fusion of multivesicular bodies with the
plasma membrane and showing fusogenic activity [5]. The role
of exosomes in conveying intercellular communication has
been extensively investigated in the immune system [6] as it is
the case when dendritic cells internalize exosomes with
specific MHC-peptide complexes and in so doing acquire new
antigen presenting specificities [7]. It has also been
demonstrated that the delivery of exosomes mediates an
antigen-driven transfer of miRNAs from the T cell to antigen
presenting cells during cognate immune interaction and
immune synapse formation [8]. Exosomes are released by
most cell types and whence, large amount of miRNAs derived
from various tissues/organs are present in human blood and
circulate in a cell-free and stable form stabilized by membrane-
bound vesicles and protected from endogenous blood RNase
activity [9]. Extracellular miRNAs are also carried by
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membrane-surrounded bodies as large as 1 µm, presumably
formed through budding/blebbing of the plasma membrane and
generally defined as microvesicles, senescent and apoptotic
bodies of similar size. Moreover, it has been observed that
circulating miRNAs can travel in blood associated with proteins,
and that their preferential association to different biological
structures could be dictated by the preferential releasing
process of the originating tissue [10].
miRNA expression changes specifically in diseases such as
cancer, autoimmunity and viral infections [11-13], making the
identification of disease-associated circulating miRNA
signatures a possible way of discovering a new class of blood-
based non-invasive biomarkers [14]. It has been already shown
that circulating miRNA profiles can discriminate healthy
subjects from patients affected by cardiovascular diseases,
multiple sclerosis, sepsis, liver injury, different tumor types, as
well as physiological states, such as pregnancy (reviewed in
15).
The aim of this work has been to investigate the use of
circulating miRNAs to monitor the physiological activation of
lymphocytes, as the one elicited by vaccination. The work has
been developed by first identifying a potential biomarker,
miR-150, based on its very high expression in lymphocytes and
strong association with vesicles released upon lymphocyte
Figure 1.  miRNA serum compartmentalization.  A. Heatmap for miRNAs significant (p<0.05) upon an ANOVA test (based on F
distribution) considering the three reported groups: nanovesicles purified by differential centrifugation (pellet at 110000Xg), total
serum and supernatants from the centrifugation at 110000Xg (soluble fraction) from sera of 3 different individuals. Data are
representative of two independent experiments. Hierarchical clustering was performed considering Log-transformed normalized
relative quantities -Log10(NRQs)- of all co-expressed miRNAs with a Ct<35. Distance: Pearson correlation with complete linkage. B.
Ranking analysis for miR-150 and miR-126 (upper panels) and for miR-19b and miR-92a (lower panels) in 10 paired samples of
total serum (TS) and purified nanovesicles (NV) (7 purified by differential centrifugation and 3 by ExoMiR). Lower ranking
position=higher representation. C. miR-19b and miR-150 relatives quantities (2^-(specific compartment Ct – total serum Ct)) by single RT-qPCR
assays in nanovesicles compared to soluble fractions from 3 healthy donors sera (mean of the three samples and SEM are
reported) processed by differential centrifugation. p value for a 2-way ANOVA analysis showing an extremely significant effect of
serum compartmentalization for different miRNAs is reported.
doi: 10.1371/journal.pone.0075348.g001
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activation in vitro. Second, we validated our hypothesis through
quantitative assessment of miR-150 in a cohort of serum
samples from pandemic flu vaccinated individuals and
ovalbumin vaccinated mice, showing an increase of serum
miR-150 upon vaccination, which correlates with antibody
response.
Material and Methods
Vaccination study design and immunogenicity
assessment
Vaccinations to adults were administered in the Department
of Biomedical Sciences for Health, University of Milan, Italy,
during the month of November 2009. Vaccinations to children
(aged 6 to 23 months) were administered in the Department of
Pathophysiology and Transplantation at Fondazione IRCCS
Policlinico Ospedale Maggiore between November 9, 2009,
and January 16, 2010 [16]. Among exclusion criteria for
children there were any treatment in the previous 4 weeks
likely to alter their immune response, previous administration of
any influenza vaccine and any acute respiratory tract infection
in the 4 weeks before enrolment. Adults received one dose and
children two doses (one month apart) of 0.5 ml of MF59-
adjuvanted monovalent 2009 pandemic influenza vaccine
(Focetria®, Novartis, Siena, Italy), containing 7.5 µg
hemagglutinin of A/California/7/2009(H1N1)(X-181). The
vaccine was injected into the deltoid muscle (adults) or into the
anterolateral part of the left thigh (children). Adult serum was
collected at time of enrolment (baseline, T0), and 1 month
(25±5 days, T1) after vaccination. Pediatric serum was
Figure 2.  Differential centrifugation and microfiltration for the identification of nanovesicle associated miRNome in human
serum.  Schematic view of the two nanovesicle purification methods used in this work: differential centrifugation (left) and
microfiltration (ExoMir, right). For the latter procedure, serum or cellular medium is passed through 2 filters connected in series. The
Top Filter has a larger pore size of approximately 200 nanometers to effectively capture larger particles while the Bottom Filter has a
smaller pore size of approximately 20 nanometers for capturing exosomes and other nanovesicles of similar size. The filters are
then disconnected and separately flushed by an RNA extraction reagent to lyse the captured particles and release their contents
with no preservation of their integrity. B. Venn diagram showing the intersection (25 miRNAs, see list in Table 1) of miRNAs highly
expressed (Ct<31 in all samples) in nanovesicles isolated by either differential centrifugation (33 total) or ExoMir (30).
doi: 10.1371/journal.pone.0075348.g002
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collected immediately before administration of dose 1 (T0),
before administration of dose 2 (28 +/- 2 days after baseline,
T1), and 4 weeks later (56 +/- 2 days after baseline, T2). 400 µl
of serum from both T0 and T1 of 46 vaccinated adults and 200
µl of serum from T0, T1 and T2 of 50 vaccinated children were
used to quantify single miRNAs. In parallel, humoral immune
response in both adults and children was assessed by using
hemagglutination inhibition test according to standard methods
(WHO Manual on Animal Influenza Diagnosis and Surveillance,
WHO/CDS/CSR/NCS/2002.5). This assay determined the
antibody titers in serum against the hemagglutinin antigens of
the 2009 pandemic influenza strain and the antibody titer was
expressed as the reciprocal of the highest dilution that inhibited
agglutination (European Committee for Proprietary Medicinal
Products Note for guidance on harmonization of requirements
for Influenza vaccines (CPMP/BWP/214/96). 1997 London:
European Agency for the Evaluation of Medicinal Products).
Purification of Mice and Human Lymphocytes and
activation experiments
Untouched CD4+ T helper and B lymphocytes were isolated
from human peripheral blood mononuclear cells (PBMC),
obtained using Ficoll-Paque on buffy coat of healthy donors,
using either CD4+ T or B lymphocytes isolation kit (Miltenyi
Biotec). CD4+ T cells were cultured in AIMV medium (devoid of
serum, and hence of contaminating miRNAs) and treated with:
i) 20 U/ml IL-2 (as un-stimulated control); ii) 100 U/ml IL-2 + 1
µg/ml Phytohemagglutinin (PHA); iii) Phorbol 12-Myristate 13-
Acetate (PMA) 25 ng/ml, Ionomycin 1µg/ml iv) 20 U/ml IL-2 +
Dynabeads anti-CD3, anti-CD28, 1 bead/cell; v)
Staphylococcus aureus enterotoxin B (SEB) 2 µg/ml. B
lymphocytes were stimulated with 2.5 µg/ml CpG, 5 µg/ml anti-
CD40 (gift of Novartis, Siena, Italy) and 10 µg/ml anti-IgM (BD
biosciences). At different time points (6, 24, 48, 72 and 96
hours for CD4+ and 24 hours for B lymphocytes) cells and
conditioned medium were harvested for cell extracts and
vesicle isolation (ExoMir kit, Bioo Scientific). Liver and spleen
were isolated from 8 weeks old C57BL/6N mice and pressed
through a cell strainer to make single-cell suspension. Liver
was resuspended in a 40% Percoll solution and mononuclear
Table 1. miRNAs strongly associated with nanovesicles
circulating in human blood.
miR-106a miR-1274B miR-17 miR-223 miR-320
miR-106b miR-142-3p miR-19a miR-24 miR-451
miR-126-5p miR-146a miR-19b miR-25 miR-720
miR-126-3p miR-150 miR-20a miR-30b miR-92a
miR-1274A miR-16 miR-222 miR-30c miR-93
miRNAs expressed in all samples of nanovesicles (from 6 healthy donors, HD)
purified by either differential centrifugation (3 HD) or ExoMir (3 HD) with a Ct<31 in
TaqMan Low Density Arrays by Applied Biosystems. Nanovesicles purified by
differential centrifugation from 2 independent healthy donors were also profiled by
using Exiqon RT-qPCR plates and miRNAs (22/25) that were also detected (Ct<35
in both samples) by this alternative platform are reported in bold.
doi: 10.1371/journal.pone.0075348.t001
cells were isolated in the pellet after centrifugation at 1900 rpm.
After the lysis of red blood cells, liver mononuclear cells were
stained with CD1d tetramer-PE, anti-CD19-FITC and anti-
TCRβ-APC antibodies while splenocytes were stained with
anti-CD19-FITC, anti-TCRβ-PECy7, anti-CD4-PE and anti-
CD8-APC antibodies. A FACS Aria (BD) was used for NKT cell
(CD19-, CD1d+, TCRβ+) sorting from liver and for either CD4+
(CD19-, TCRβ+, CD4+, CD8-) or CD8+ (CD19-, TCRβ+, CD4-,
CD8+) T lymphocyte sorting from spleen. Purified NKT, CD4+,
CD8+ T lymphocytes were cultured separately in AIMV medium
and stimulated with PMA 25 ng/ml, Ionomycin 1µg/ml. Cells
were collected for RNA extraction before (0 hours) and after
(72 hours) activation. Conditioned medium (72 hours) was
processed with ExoMir kit for exosome purification.
Vesicle Preparation
For differential centrifugation, 2 ml of serum diluted to 4 ml in
phosphate buffered saline (PBS) were centrifuged to eliminate
floating cells (300Xg), dead cells (2,000Xg), cellular debris and
apoptotic bodies (serum: 12,000Xg; cell medium: 10,000Xg).
The final supernatant was then ultracentrifuged at 110,000Xg
(100,000Xg for cell medium) to pellet the nanovesicles. The
pellet was then re-suspended in PBS and filtered through a 0.2
micron filter to eliminate residual larger particles, washed in a
large volume of PBS, to eliminate contaminating proteins, and
centrifuged at the same speed. For microfiltration (ExoMir kit,
Bioo Scientific) 0.6-8 ml of cellular medium or 0.4 ml of human
serum diluted to 4 ml with PBS were centrifuged at 300Xg and
then at 2,000Xg. Supernatants were digested by Proteinase K
to eliminate protein complexes and then passed through
ExoMir filters. After washing the Top/Bottom filters with 12 ml of
PBS (double wash for serum), microvesicles and
nanovescicles were separately eluted using 1ml of BiooPure-
MP plus ath-mir-159a (final concentration 3 pM).
miRNA profiling and single miRNA detection by RT-
qPCR and Northern Blot
Total RNA from either fresh or frozen human sera and from
either cells or centrifuged vesicular pellets was extracted using
miRVana miRNA isolation kit (Ambion), as specified in the
protocol, with some modifications. Briefly, 400 µl of thawed
serum were mixed with 800 µl of lysis solution composed of
RNA Lysis Buffer and synthetic ath-miR-159a (final
concentration 2.5 pM). This miRNA was used as process
control, for technical normalization. RNA extraction from
ExoMir Filters was performed as specified in the protocol and
RNA was quantified by Ribogreen (Invitrogen), and
characterized by Agilent Bioanalyzer. 3 µl of total RNA were
processed for Reverse Transcription and Preamplification with
Megaplex Primer Pools A v2.1 and B v2.0 (Applied
Biosystems), according to manufacturer instruction. TaqMan
Low Density Arrays (Applied Biosystems) were run on a
7900HT Fast Real-Time PCR System. A total of 664 human
miRNAs, 6 human small RNA and 1 control miRNA from A.
Thaliana were profiled in parallel. Ct values were extracted
using RQ Manager, setting a manual threshold of 0.06. For
single miRNA detection, a multiplexed Reverse Transcription
reaction (up to 5 miRNAs) was implemented using the TaqMan
Serum microRNAs as Biomarkers of Immune Response
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miRNA Reverse Transcription Kit and miRNA-specific stem-
loop primers (Applied Biosystems) according to manufacturer
instruction. To profile miRNA expression in human tissues or
cultured cells, 10 ng of RNA were processed for RT-qPCR
(FirstChoice Human Total RNA Survey Panel, Ambion). DCt
values were obtained using the Ct of MammU6 as endogenous
control. Serum samples and serum purified nanovesicles were
also profiled for 742 miRNAs by using miRNA Ready-to-Use
PCR, Human Panel I+II, V2.M RT-qPCR arrays (Exiqon).
Normalized values were obtained using a normalization factor
resulting from the geometric mean of all expressed miRNAs
per sample, i.e. the mean obtained omitting detectors with a Ct
>35. For Northern Blotting, we have used 3’ and 5’
Digoxigenin-labeled miRCURY Locked Nucleic Acid (LNA™)
microRNA Detection Probes (Exiqon) according to
manufacturer instructions.
Figure 3.  Nanovesicular miRNome of the lymphocyte extracellular milieu is not a mere representation of the intracellular
miRNome from parental cells.  A. Bio-analyzer qualitative analysis of total RNA extracted 72 hours after activation with
Phytohemagglutinin (PHA) from CD4+ T lymphocytes (upper panel) and released nanovesicles purified by ExoMir (lower panel). A
representative sample is reported. B. Fold change (96 hours compared to 6 hours upon activation with PHA) and SEM of miRNome
relative quantities of nanovesicle samples (in biological triplicate) released by CD4+ T lymphocyte. Two profiling platforms were used
(as indicated, Applied Biosystems Stem-loop RT-qPCR and Exiqon Locked Nucleic Acid (LNA)-based RT-qPCR) and only miRNAs
with a Ct<35 were considered. p values of a Wilcoxon matched-pairs signed rank test comparing 6 hours and 96 hours upon
activation are reported. C. Hierarchical clustering of Z score values for miRNAs significant (p<0.01) upon a paired t test considering
normalized relative quantities of all co-expressed miRNAs with a Ct<35 in CD4+ T cellular and nanovesicular compartments (NV) at
the indicated time points upon activation with PHA in vitro. Biological triplicates are reported. Distance for hierarchical clustering on
significant miRNA: Pearson correlation with average linkage. D. Hierarchical clustering of Z score values for normalized relative
quantities of miRNome from CD4+ T and B lymphocytes and their relative released extracellular nanovesicles. Only the 101 co-
expressed miRNAs with a Ct<35 were considered. Biological triplicates are reported. Distance: Pearson correlation with average
linkage.
doi: 10.1371/journal.pone.0075348.g003
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Mice studies
MHCII−/− (B6.129-H2Ab1tm1Doi/DoiOrl) and C57BL6/N
(Charles River, Italy) were maintained in specific pathogen-free
conditions and used at 8 weeks of age. Following collection of
pre-immunization sera, four groups of mice were primed at day
0 by subcutaneously (in the left flank) injection of 100 μg/dose
of Ovalbumin protein (Sigma) mixed with i) 0.1μg/dose of
alpha-galactosylceramide (αGalCer, Alexis), ii) Imject Alum
Adjuvant (Pierce, Thermo Scientific), iii) phosphate buffered
saline. Blood was then drawn by retro-orbital phlebotomy 7 and
14 days after to determine specific Ig titers of the primary
responses on sera. For measurement of antigen-specific
antibody titers, individual sera were titrated in parallel at the
same time by ELISA and antibody titers are expressed as
reciprocal dilutions giving an OD450 > mean blank OD450 + 3
SD. Furthermore, for measurement of circulating miRNAs, 50
µl of sera of pre-vaccinated and 7 and 14 days post-vaccinated
mice were processed for total RNA extraction and miR-150
was quantified by single TaqMan assay.
Ethics Statement
Both the use of biological material (serum and buffy-coat
blood) from healthy donors for research purposes and human
vaccination studies were approved by the Ethics Committee of
IRCCS Ca’ Granda Policlinico Ospedale Maggiore in Milan,
Italy. Written informed consent regarding study participation
was obtained from all involved adults and the parents or legal
guardians of children. All animal procedures were reviewed
and approved by the Institutional Animal Care and Use
Committee at San Raffaele Scientific Institute.
Results
Identification of a miRNA signature associated with
nanovesicles in human blood
To identify a signature of miRNAs being strongly represented
in nanovesicles circulating in human blood, we used TaqMan
Table 2. Differential expression of miRNAs in nanovesicles
released by CD4+ lymphocytes compared to the intracellular
compartment.
Nanovesicle depleted miRNAs
miR-26a miR-31 miR-142-3p miR-26b
miR-106a miR-30c let-7g miR-17
miR-30b miR-146b miR-20a  
Nanovesicle enriched miRNAs
miR-483-5p miR-767-3p miR-151-3p miR-323-3p
miR-378 miR-618 miR-146a miR-491
miR-494 miR-138 miR-320 miR-146b-3p
miR-601 miR-181a miR-186 miR-323-5p
List of miRNAs significantly (p<0.01) either depleted (up) or enriched (down) in
nanovesicular compared to intracellular compartment upon a paired t test
considering normalized relative quantities of all co-expressed miRNAs with a
Ct<35 (Figure 3C).
doi: 10.1371/journal.pone.0075348.t002
Low Density Arrays (TLDA) to profile by RT-qPCR the
miRNome in serum nanovesicles purified by differential
centrifugation, in comparison with the miRNome from serum
soluble fraction and total serum. Nanovesicle-associated
miRNAs clustered more distantly than miRNAs found in total
serum and soluble fraction, suggesting a specific nanovesicular
miRNA quantitative profile. Indeed, some miRNAs were found
to be enriched in nanovesicles, while others were more
represented in total serum and soluble fraction samples (Figure
1A and Table S1 for raw data). The preferential association of
specific miRNAs with nanovesicles was also confirmed by
ranking analysis and RT-qPCR single assays (Figure 1B,C).
We then purified nanovesicles from sera by using ExoMir, an
alternative method of purification based on microfiltration. The
general workflow for both differential centrifugation [17] and
microfiltration [18] is depicted in Figure 2A. By intersecting
results of the two purification strategies, we obtained a list of 25
miRNAs that could be regarded as strongly associated with
circulating nanovesicles, independently of the purification
method. Moreover, 22/25 of these miRNAs were also found
consistently expressed by profiling nanovesicular miRNome on
a different RT-qPCR platform (Table 1).
Remarkably, miR-150, a key regulator of lymphocyte
differentiation and functions, was not only part of the signature
of miRNAs strongly associated with circulating nanovesicles,
but also specifically enriched in this compartment.
Concomitant intracellular down-modulation and
extracellular enrichment of miR-150 in nanovesicles
upon lymphocyte activation
In order to identify miRNAs associated with nanovesicles
released in the extracellular milieu by human lymphocytes
upon activation in vitro, primary CD4+ T cells were stimulated
with Phytohemagglutinin (PHA) and IL-2, while primary B cells
were activated with a combination of CpG, anti-CD40 mAb and
anti-IgM. Extracellular nanovesicles were then purified from
culture media at different time points after activation.
Qualitative analysis of total RNA showed a significant
enrichment of small RNA molecules in purified nanovesicles
compared to cells (Figure 3A). Over time, miRNAs
accumulated in the extracellular space, leading to a sharp
increase of miRNA relative expression global mean (Figure
3B). Significantly, the extracellular miRNome of primary
lymphocytes was not a mere representation of the intracellular
one: 27 miRNAs were found to be either up- or down-
represented significantly in nanovesicular compared to
intracellular compartments of CD4+ T lymphocytes (Figure 3C
and Table 2). Moreover, the miRNome associated with
nanovesicles released by CD4+ T and B activated lymphocytes
was more similar than the one expressed by the relative
parental cells, as shown by clustering analysis (Figure 3D).
Similarly to what described in the mouse system [19], in human
primary CD4+ T lymphocytes miR-150 was significantly down-
modulated upon activation. In parallel, we found it to get
accumulated in extracellular nanovesicles (Figure 4A and
Table S2 for raw data). Ranking analysis also showed miR-150
to be among the most represented miRNAs associated with
nanovesicles purified in the extracellular milieu of both CD4+ T
Serum microRNAs as Biomarkers of Immune Response
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and B stimulated lymphocytes (Table 3). Intracellular down-
modulation of miR-150 upon activation of lymphocytes was
paralleled by a slight but significant up-regulation of one of its
most relevant targets, c-Myb (Figure 4B). miR-150 intracellular
down-modulation and nanovesicular accumulation were
dependent on cellular activation, as they were significantly
more pronounced in CD4+ T lymphocytes activated by different
stimuli compared to the same cells growing in IL-2 enriched
media as control (fold changes relative to control treatment are
shown in Figure 4C). Very similar results were obtained by
Figure 4.  miR-150 intracellular down-modulation and release upon in vitro activation of CD4+ T lymphocytes.  A. Heatmap
showing the expression fold change of the indicated miRNAs at the indicated time points upon activation with Phytohemagglutinin
(PHA) of CD4+ T lymphocytes compared to Time 0 (T0=1) (left panel); and Log10 transformed relative expression of the same
miRNAs in samples of nanovesicles collected at the indicated time points (right panel). Values are mean of a biological triplicate.
The down-regulated (all 5) and the up-regulated (representative 5/56) miRNAs were selected by an ANOVA test (based on F
distribution). B. Column chart plotting mean and SEM (of a biological triplicate) of fold change of CD4+ T lymphocyte intracellular
miR-150 down-regulation and parallel c-Myb up-regulation (normalized by expression of internal control MammU6 and relative to
Time 0) at the indicated time points upon activation with PHA. Asterisks indicate a t test resulting in a p value<0.05. C. Column
charts plotting mean and SEM (of a biological triplicate) of fold change of CD4+ T lymphocyte intracellular miR-150 modulation
(normalized by expression of internal control MammU6 and relativized to control, i.e. treatment with IL-2 alone) and nanovesicular
accumulation (expressed as relative quantities of extracellular nanovesicular miR-150 upon activation compared to control IL-2
alone treated cells) 72 hours upon starting the indicated treatments (PMA for Phorbol 12-Myristate 13-Acetate; PHA for
Phytohemagglutinin; SEB for Staphylococcus aureus enterotoxin B). Two profiling platforms were used (as indicated, Applied
Biosystems Stem-loop RT-qPCR and Exiqon Locked Nucleic Acid (LNA)-based RT-qPCR) to validate results obtained treating cells
with either PHA or SEB (right panel). D. Correspondence between RT-qPCR (upper panel) and Northern Blot (lower panel) for
MammU6 snRNA (used as endogenous control, left) and miR-150 (right) expression level at time 0 and 72 hours upon starting the
indicated treatments.
doi: 10.1371/journal.pone.0075348.g004
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using three different techniques of miRNA detection (stem-loop
RT-qPCR and Locked Nucleic Acid (LNA)-based Universal RT-
qPCR, Figure 4C; Northern blot, Figure 4D).
Serum circulating miR-150 increases after vaccination
Having observed that lymphocytes activated in vitro release
high quantities of miR-150, and that this miRNA is easily
detectable in human serum, we sought to evaluate whether the
level of circulating miR-150 would be modulated upon
lymphocyte activation in vivo, as upon vaccinations. We chose
to analyze sera of healthy individuals vaccinated for the
influenza virus A/H1N1, the pandemic flu of 2009. The specific
vaccine was shown to be immunogenic, safe and well
tolerated, being an optimal choice for a starting study.
Moreover, the adjuvant MF-59 was already known to evoke
greater, long-lasting and broader immune responses [20]. We
assessed miR-150 relative quantity by RT-qPCR in serum
samples of 50 healthy children and 46 healthy adults before
(T0) and 30 days (T1) after immunization with pandemic flu
vaccine (for children, all aged <36 months and never
vaccinated against influenza, who were administered a second
vaccine dose, we had also serum collected 30 days after the
second dose, T2). As hypothesized, miR-150 serum level
increased after vaccination in adults at T1 and in children after
the second dose (T2) (Figure 5A). Differences between the two
sample sets are likely due to a partial immunity linked to
established memory for seasonal flu that would be present in
adults but not in children [21]. miR-1274B, which is strongly
associated with vesicles released by lymphocytes as well as by
non-lymphoid cells (Table 3), failed to show any modulation in
sera of vaccinees (data not shown).
Serum samples from 17 adults vaccinated with H1N1 MF59
(T0 and T1 as above) were also used to purify nanovesicles
and vesicles of larger size (between 0.2 and 1 µm, here called
microvesicles) using ExoMir. Remarkably, upon vaccination
circulating miR-150 increased more significantly in isolated
Table 3. miR-150 is among the most represented miRNAs
associated with nanovesicles released by human activated
lymphocytes.
T lymph. B lymph. HuH7.5 HeLa
miR-1274B miR-299-3p miR-628-5p miR-1290
miR-1274A miR-1274B miR-1274B miR-1305
miR-150 miR-1290 miR-1290 miR-1274B
miR-720 miR-150 miR-27a miR-661
miR-19b miR-875-5p miR-518f miR-1274A
miR-155 miR-661 miR-1274A miR-720
miR-223 miR-223 miR-520c miR-483-5p
miR-29a miR-483-5p miR-720 miR-601
miR-222 miR-601 miR-299-3p miR-24
miR-17 miR-422a miR-661 miR-222
Representation ranking for the ten most represented miRNAs associated with
nanovesicles released by the indicated cells after either 72 (CD4+ T lymphocytes)
or 24 hours of cell culture (B lymphocytes, HuH7.5 and HeLa).
doi: 10.1371/journal.pone.0075348.t003
nanovesicles than in total serum, whereas it did not changed in
isolated microvesicles, suggesting a specific process of
miR-150 release through nanovesicles during immune
response (Figure 5B). The Receiver Operating Characteristic
(ROC) curves for total serum, nanovesicular and
microvesicular miR-150 and the area under the curve (AUC)
values confirmed the ability of nanovesicular miR-150 to
distinguish serum samples on the basis of vaccination (Figure
5C).
The increase of serum circulating miR-150 depends on
adaptive immune response in humans and mice
The observations that miR-150 is both the most highly
expressed miRNA in 17 different lymphocyte subsets from
peripheral blood mononuclear cells of healthy donors and
highly abundant in spleen, lend supports to the evidence that
the major source of serum miR-150 are lymphoid cells [(Figure
6 and [22]]. Then, if miR-150 is selectively released by
activated lymphocytes, then there could be a correlation
between its recordable level and the magnitude of the immune
response. Indeed, in flu vaccinated adults, miR-150 serum
levels at T1 were significantly higher in individuals mounting
higher antibody response (as surveyed by a hemagglutinin
inhibition test assay). miR-1274B was added as a control
(Figure 7A).
Mouse T lymphocytes showed a pattern of nanovesicular
accumulation upon activation in vitro similar to the one
observed in human lymphocytes, with no major differences
between CD4+, CD8+ or iNKT cells (Figure 7B). Furthermore,
consistently with results obtained in vaccinated individuals,
mice immunized with ovalbumin (OVA) and alpha-
galactosylceramide (αGalCer), an adjuvant leading to a strong
activation of lymphocyte response through NKT activation [23],
showed a tidy increase of serum miR-150 seven days after
vaccination (Figure 7C). When MHCII-/- mice, that are depleted
of mature CD4+ T lymphocytes [24], were vaccinated in the
same way, circulating miR-150 increment was significantly
lower in comparison with wild type mice (Figure 7C), confirming
the specificity of the observed phenomenon. Moreover, the
increment of circulating miR-150 upon vaccination (expressed
as fold change T1/T0) was found to significantly correlate with
the level of antibodies in wild type mice vaccinated with OVA
mixed with either αGalCer or Alum (Figure 7D). In contrast, in
mice vaccinated with non-adjuvanted OVA, no antibody
production was revealed and circulating miR-150 increase was
not detectable after vaccination (Figure 7D). These results
together strongly suggest that the increment in the level of
circulating miR-150 upon immunization is lymphocyte-derived
and dependent on the magnitude of immune response.
Discussion
Expression of intracellular miRNAs and their target genes
have been extensively studied in activated CD4+ T cells [3,25].
For instance, down-regulation of mouse miR-150 upon
activation [26] associates with up-regulation of its target c-Myb,
a transcriptional factor that promotes lymphocyte survival by
inducing the pro-survival protein Bcl2 [27]. We report here that
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upon activation of both human and mouse primary
lymphocytes, there is a reduction of miR-150 intracellular
expression concomitantly with an extracellular accumulation of
exosome-associated mir-150. We speculate that the release of
miR-150 rich vesicles may represent a new and additional layer
of regulation of miR-150 expression level and, in turn, of the
mRNAs that are targeted by this miRNA and critically control
lymphocyte responses.
It has been recently shown that reduced miR-150 serum
concentrations are associated with an unfavorable outcome in
critically ill patients with sepsis and it has been hypothesized
that lower level of circulating miR-150 might lead to a de-
repression of genes such as CXCR4 and c-Myb, that are linked
to immune response activation and poor prognosis [28]. In line
with this hypothesis, it is tempting to speculate that the
increase of circulating miR-150 level that we observe upon
vaccination may be part of a negative regulatory loop aimed at
down-modulating adaptive immune responses through the
transmission of extracellular messages to other immune cells
and the consequent regulation of miR-150 target genes. This
possibility is not unprecedented as the delivery of miRNAs by
transfer through nanovesicles is a recently described
mechanism of cell-cell communication, potentially occurring at
a distance [29]. In particular, it has been demonstrated that
vesicle-packaged miR-150 specifically regulates target gene
expression and function in recipient cells [30]. Furthermore, an
RNA-based paracrine mode of signal transmission may be also
well suited in controlling space-confined processes, such as
initiation and development of adaptive immune responses in
secondary lymphoid organs. The transfer of proteins and
nucleic acids such as small RNA between T cells and antigen-
presenting cells has indeed been described, involving
exchange of extracellular vesicles during the formation of the
immunological synapse [8]. As nanovesicles can deliver
Figure 5.  Circulating miR-150 modulation in human serum upon flu vaccination.  A. miR-150 quantities relative to exogenous
spike-in ath miR-159a in sera of 50 H1N1-MF59 vaccinated children (samples collected at time of first dose, T0, at time of second
dose 30 days after, T1 and 30 days after the second dose, T2) (left) and 46 pairs of samples (time of vaccination, T0 and 30 days
after, T1) from H1N1-MF59 vaccinated healthy adults (right). Data were centered on the mean at T0 and mean values, SEM and
two-tailed paired t test p values are reported. B. Box plot of miR-150 quantities relative to exogenous spike-in ath miR-159a
(whiskers: 10-90 percentile) in the indicated serum compartments of 17 pairs of H1N1-MF59 at T0 (white) and T1 (grey). Two-tailed
paired t test p values are reported. C. Receiver Operating Characteristic (ROC) curves for total serum, nanovesicular and
microvesicular miR-150 increment in H1N1-MF59 vaccinated adults compared to pre-vaccination level (SE=Sensitivity; SP=
Specificity). Area under the curve (AUC) and p value (calculated with χ2 test) for nanovesicular miR-150 are reported.
doi: 10.1371/journal.pone.0075348.g005
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multiple miRNAs, functionally related genes could be
suppressed simultaneously, leading to a very effective control
over neighboring cells [31]. Hence, a characterization of
cellular targets of the above miRNAs may provide new insight
into functionally relevant biological patterns of immune cells,
which could be targeted by new immune-modulatory
pharmacological approaches.
During immune response, it is likely that miRNAs are
released into the surrounding environment via active release of
nanovesicles by activated lymphocytes [6]. Here we describe a
specific modulation of circulating miR-150 upon immunization,
more evident in purified nanovesicles compared to total serum,
that is suggestive of a phenomenon of massive release of
nanovesicle associated miRNAs occurring in vivo during the
physiological activation of the immune system. Hence our
study supports the hypothesis that analyzing miRNA levels in
serum is a promising area for identifying new biomarkers of
immune response and that purification of nanovesicles may be
a useful step to enrich for miRNAs segregating to specific
structures, and increase sensitivity for the immune response.
miR-150 is highly expressed in all lymphocyte populations,
hence it is a very general sensor of adaptive immune response
but our study also suggests that different lymphocyte
populations may display significantly different selective
enrichment of specific extracellular miRNAs. Thus, upon their
identification, it would be virtually possible to mark the
elicitation of different lymphocyte populations through the
assessment of their specific serum signatures [32]. The
identification of these signatures may then become an
innovative tool to provide pivotal information about the nature
of the immune response in diseases involving the immune
system or during clinical trials with new vaccines, adjuvants
and immune-modulatory drugs.
Figure 6.  miR-150 expression in human resting lymphocytes and tissues.  A. Box plot of miRNome relative quantities in 17
different lymphocyte subsets, as indicated (blue, B; red, CD4+ T; green, CD8+ T; grey, NK). Only co-expressed miRNAs with a
Ct<35 were considered. White circles indicate miR-150 expression level. B. miR-150 level in a panel of 20 different human tissues
(as indicated) by RT-qPCR, relative to the internal control MammU6, and reported in percentage relative expression among tissues.
doi: 10.1371/journal.pone.0075348.g006
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Figure 7.  Correlation between circulating miR-150 modulation and immune response.  A. Box plot of indicated miRNA
quantities at T1 (30 days after vaccination) relative to exogenous spike-in ath miR-159a (whiskers: 10-90 percentile) in 46 flu
vaccinated individuals stratified for having developed an antibody response lower (white) or higher (grey) than 1:320, as assessed
by hemagglutination inhibition test assay. The p value of a Mann Whitney test is reported. B. Column chart plotting mean and SEM
(of a biological triplicate) of mature miR-150 relative quantities in the indicated mouse lymphocytes: intracellular level 72 hours upon
activation was normalized first by expression of internal control MammU6 snRNA and then by level at T0. Extracellular accumulation
was calculated as 2^-{Ct(intracellular)-Ct(nanovesicles)}miR-150 / 2^-{Ct(intracellular)-Ct(nanovesicles)}MammU6. Data are representative of two independent
experiments. C. miR-150 quantities relative to exogenous spike-in ath miR-159a in wild type and MHCII-/- mice vaccinated with
ovalbumin (OVA) adjuvanted with alpha-galactosylceramide (αGalCer) 2 days before vaccination (-2, or T0) and 7 days after
vaccination (each treatment normalized to miR mean relative quantity at T0). p value for a paired t test is reported. Four wild type
mice and four MHCII-/- mice were used for vaccination experiment. D. Correlation between anti-OVA total Ig concentration
(assessed by ELISA) at T=7 days after vaccination in mice vaccinated with αGalCer + OVA (black) or Alum + OVA (grey) and serum
circulating miR-150 fold change T1/T0 (T1=7 days after vaccination). Spearman r and p value are reported. miR-150 fold changes
values for mice vaccinated with non-adjuvanted OVA are also reported (white).
doi: 10.1371/journal.pone.0075348.g007
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Supporting Information
Table S1.  miRNA serum compartmentalization. Raw data
(Ct values) for miRNAs profiled by Applied Biosystems Stem-
loop RT-qPCR from the three reported groups: nanovesicles
purified by differential centrifugation (pellet at 110000Xg), total
serum and supernatants from the centrifugation at 110000Xg
(soluble fraction) from sera of 3 different individuals. Data are
from one of two independent experiments that gave
comparable results.
(TXT)
Table S2.  Nanovesicular miRNome of the lymphocyte
extracellular milieu is not a mere representation of the
intracellular miRNome from parental cells. Raw data (Ct
values) for miRNAs profiled by Applied Biosystems Stem-loop
RT-qPCR from CD4+ T cellular and nanovesicular
compartments at the indicated time points upon activation with
PHA in vitro. Biological triplicates are reported. Following,
miRNome from B lymphocytes and their relative released
extracellular nanovesicles at the indicated time point of
activation.
(TXT)
Acknowledgements
Many thanks to Lucio Luzzatto, Giuseppe Matarese, and
Chiara Zingaretti for helpful discussions.
Author Contributions
Conceived and designed the experiments: PdC SA. Performed
the experiments: PdC AT TG MF EB MC MM. Analyzed the
data: PdC AT CC F. Marabita. Contributed reagents/materials/
analysis tools: EP LR F. Mosca SE GR RLR JG GC PD. Wrote
the manuscript: PdC MP SA.
References
1. Bartel DP (2009) MicroRNAs: target recognition and regulatory
functions. Cell 136: 215-233. doi:10.1016/j.cell.2009.01.002. PubMed:
19167326.
2. Xiao C, Rajewsky K (2009) MicroRNA control in the immune system:
basic principles. Cell 136: 26-36. doi:10.1016/j.cell.2008.12.027.
PubMed: 19135886.
3. Bronevetsky Y, Ansel KM (2013) Regulation of miRNA biogenesis and
turnover in the immune system. Immunol Rev 253: 304-316. doi:
10.1111/imr.12059. PubMed: 23550654.
4. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ et al. (2007)
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol 9:
654-659. doi:10.1038/ncb1596. PubMed: 17486113.
5. Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes,
microvesicles, and friends. J Cell Biol 200: 373-383. doi:10.1083/jcb.
201211138. PubMed: 23420871.
6. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as
conveyors of immune responses. Nat Rev Immunol 9: 581-593. doi:
10.1038/nri2567. PubMed: 19498381.
7. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV et
al. (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp
Med 183: 1161-1172. doi:10.1084/jem.183.3.1161. PubMed: 8642258.
8. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S,
Sánchez-Cabo F et al. (2011) Unidirectional transfer of microRNA-
loaded exosomes from T cells to antigen-presenting cells. Nat Commun
2: 282. doi:10.1038/ncomms1285. PubMed: 21505438.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A 105: 10513-10518. doi:10.1073/
pnas.0804549105. PubMed: 18663219.
10. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC et al. (2011)
Argonaute2 complexes carry a population of circulating microRNAs
independent of vesicles in human plasma. Proc Natl Acad Sci U S A
108: 5003-5008. doi:10.1073/pnas.1019055108. PubMed: 21383194.
11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A et al. (2006) A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci U S A 103: 2257-2261. doi:10.1073/
pnas.0510565103. PubMed: 16461460.
12. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007)
MicroRNA-155 is induced during the macrophage inflammatory
response. Proc Natl Acad Sci U S A 104: 1604-1609. doi:10.1073/pnas.
0610731104. PubMed: 17242365.
13. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005)
Modulation of hepatitis C virus RNA abundance by a liver-specific
MicroRNA. Science 309: 1577-1581. doi:10.1126/science.1113329.
PubMed: 16141076.
14. Chen X, Ba Y, Ma L, Cai X, Yin Y et al. (2008) Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of
cancer and other diseases. Cell Res 18: 997-1006. doi:10.1038/cr.
2008.282. PubMed: 18766170.
15. Reid G, Kirschner MB, van Zandwijk N (2011) Circulating microRNAs:
Association with disease and potential use as biomarkers. Crit Rev
Oncol/Hematol 80: 193-208. doi:10.1016/j.critrevonc.2010.11.004.
PubMed: 21145252.
16. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A et al. (2011)
Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term
children aged 6 to 23 months. Pediatrics 127: e1161-1168. PubMed:
21464195.
17. Théry C, Amigorena S, Raposo G, Clayton A (2006) Isolation and
characterization of exosomes from cell culture supernatants and
biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3.22: Unit 3 22.
PubMed: 18228490
18. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL et al.
(2012) Changes in circulating microRNA levels associated with prostate
cancer. Br J Cancer 106: 768-774. doi:10.1038/bjc.2011.595. PubMed:
22240788.
19. Monticelli S, Ansel KM, Xiao C, Socci ND, Krichevsky AM et al. (2005)
MicroRNA profiling of the murine hematopoietic system. Genome Biol
6: R71. doi:10.1186/gb-2005-6-8-r71. PubMed: 16086853.
20. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A et al.
(2009) Enhanced immunogenicity of seasonal influenza vaccines in
young children using MF59 adjuvant. Pediatr Infect Dis J 28: 563-571.
doi:10.1097/INF.0b013e31819d6394. PubMed: 19561422.
21. Chen H, Wang Y, Liu W, Zhang J, Dong B et al. (2009) Serologic
survey of pandemic (H1N1) 2009 virus, Guangxi Province, China.
Emerg Infect Dis 15: 1849-1850. doi:10.3201/eid1511.090868.
PubMed: 19891883.
22. Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A et al. (2011)
Distinct microRNA signatures in human lymphocyte subsets and
enforcement of the naive state in CD4+ T cells by the microRNA
miR-125b. Nat Immunol 12: 796-803. doi:10.1038/ni.2057. PubMed:
21706005.
23. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y et al. (2007) Invariant
NKT cells sustain specific B cell responses and memory. Proc Natl
Acad Sci U S A 104: 3984-3989. doi:10.1073/pnas.0700191104.
PubMed: 17360464.
24. Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH (1991)
Depletion of CD4+ T cells in major histocompatibility complex class II-
deficient mice. Science 253: 1417-1420. doi:10.1126/science.1910207.
PubMed: 1910207.
25. Bronevetsky Y, Villarino AV, Eisley CJ, Barbeau R, Barczak AJ et al.
(2013) T cell activation induces proteasomal degradation of Argonaute
and rapid remodeling of the microRNA repertoire. J Exp Med 210:
417-432. doi:10.1084/jem.20111717. PubMed: 23382546.
26. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC et al. (2007)
MiR-150 controls B cell differentiation by targeting the transcription
factor c-Myb. Cell 131: 146-159. doi:10.1016/j.cell.2007.07.021.
PubMed: 17923094.
27. Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B (1997)
Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb
Serum microRNAs as Biomarkers of Immune Response
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e75348
is associated with induction of BCL-2 expression and Myb-dependent
regulation of bcl-2 promoter activity. Proc Natl Acad Sci U S A 94:
3296-3301. doi:10.1073/pnas.94.7.3296. PubMed: 9096387.
28. Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Scholten D et
al. (2013) Circulating microRNA-150 serum levels predict survival in
patients with critical illness and sepsis. PLOS ONE 8: e54612. doi:
10.1371/journal.pone.0054612. PubMed: 23372743.
29. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK et
al. (2011) MicroRNAs in body fluids--the mix of hormones and
biomarkers. Nat Rev Clin Oncol 8: 467-477. doi:10.1038/nrclinonc.
2011.76. PubMed: 21647195.
30. Zhang Y, Liu D, Chen X, Li J, Li L et al. (2010) Secreted monocytic
miR-150 enhances targeted endothelial cell migration. Mol Cell 39:
133-144. doi:10.1016/j.molcel.2010.06.010. PubMed: 20603081.
31. Lotvall J, Valadi H (2007) Cell to cell signalling via exosomes through
esRNA. Cell Adh Migr 1: 156-158. doi:10.4161/cam.1.3.5114. PubMed:
19262134.
32. Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ et al. (2013)
Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell
differentiation. Immunol Rev 253: 82-96. doi:10.1111/imr.12055.
PubMed: 23550640.
Serum microRNAs as Biomarkers of Immune Response
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e75348
